J&J Confirms EU Stelara Biosimilars Are Imminent
Key SPC Expiry Opens Up Sizeable Opportunity For Biosimilars
Executive Summary
One of the largest biologic opportunities for inflammatory bowel disorders, Johnson & Johnson’s Stelara, will open up to biosimilar competition in a matter of days, the originator has confirmed.